Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WF10 in late-stage HIV disease
NCT00002244Phase 3Completed
- Sponsor
- OXO Chemie AG
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing WF10 with Placebo (2 arms). Primary endpoint: Clinical Progression at 96 weeks. Status: completed.
02
Drugs
tetrachlorodecaoxide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002244.